News
MSD rumoured to be nearing $6bn play for Terns Pharma
MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff is reported to be continuing with a $6bn bid to acquire Terns Pharma.
News
Karyopharm eyes Xpovio filing in myelofibrosis on mixed data
Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.
News
MSD taps Quotient for IBD drug targets in $2.2bn deal
MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.
News
Gilead buys autoimmune disease biotech Ouro for $2.2bn
Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
